JP7771049B2 - 新化合物 - Google Patents

新化合物

Info

Publication number
JP7771049B2
JP7771049B2 JP2022516299A JP2022516299A JP7771049B2 JP 7771049 B2 JP7771049 B2 JP 7771049B2 JP 2022516299 A JP2022516299 A JP 2022516299A JP 2022516299 A JP2022516299 A JP 2022516299A JP 7771049 B2 JP7771049 B2 JP 7771049B2
Authority
JP
Japan
Prior art keywords
methyl
imidazol
urea
phenyl
thienylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549086A (ja
JPWO2021053344A5 (https=
JP2022549086A5 (https=
Inventor
フェックス，トマス
オルソン，ベンクト
Original Assignee
ヴィコール ファルマ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィコール ファルマ アーベー filed Critical ヴィコール ファルマ アーベー
Publication of JP2022549086A publication Critical patent/JP2022549086A/ja
Publication of JPWO2021053344A5 publication Critical patent/JPWO2021053344A5/ja
Publication of JP2022549086A5 publication Critical patent/JP2022549086A5/ja
Priority to JP2025186669A priority Critical patent/JP2026041728A/ja
Application granted granted Critical
Publication of JP7771049B2 publication Critical patent/JP7771049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022516299A 2019-09-20 2020-09-18 新化合物 Active JP7771049B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025186669A JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
GB1913603.5 2019-09-20
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025186669A Division JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Publications (4)

Publication Number Publication Date
JP2022549086A JP2022549086A (ja) 2022-11-24
JPWO2021053344A5 JPWO2021053344A5 (https=) 2023-09-06
JP2022549086A5 JP2022549086A5 (https=) 2023-09-06
JP7771049B2 true JP7771049B2 (ja) 2025-11-17

Family

ID=68425648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516299A Active JP7771049B2 (ja) 2019-09-20 2020-09-18 新化合物
JP2025186669A Pending JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025186669A Pending JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Country Status (15)

Country Link
US (2) US12435072B2 (https=)
EP (1) EP4031240A1 (https=)
JP (2) JP7771049B2 (https=)
KR (1) KR20220101071A (https=)
CN (1) CN114786774A (https=)
AU (1) AU2020351301B2 (https=)
BR (1) BR112022003130A2 (https=)
CA (1) CA3152218A1 (https=)
CL (1) CL2022000656A1 (https=)
CO (1) CO2022003091A2 (https=)
GB (1) GB201913603D0 (https=)
IL (1) IL291172A (https=)
MX (2) MX2022003286A (https=)
PH (1) PH12022550564A1 (https=)
WO (1) WO2021053344A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
MX2024000518A (es) * 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
CA3247073A1 (en) * 2022-04-06 2025-02-03 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company AT2R AGONIST
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068226A1 (de) 1999-05-05 2000-11-16 Aventis Pharma Deutschland Gmbh 1-(p-thienylbenzyl)-imidazole als agonisten von angiotensin-(1-7)-rezeptoren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
JP2004533457A (ja) 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2008535898A (ja) 2005-04-12 2008-09-04 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンｉｉアゴニスト
JP2015504870A (ja) 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
JP2018507244A (ja) 2015-03-02 2018-03-15 ビーコレ ファルマ アクティエボラーグ 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
JP2019519586A (ja) 2016-06-29 2019-07-11 ユニヴェルシテ・ドゥ・モントリオール ビアリールメチルヘテロサイクル

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068226A1 (de) 1999-05-05 2000-11-16 Aventis Pharma Deutschland Gmbh 1-(p-thienylbenzyl)-imidazole als agonisten von angiotensin-(1-7)-rezeptoren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
JP2002544130A (ja) 1999-05-05 2002-12-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アンギオテンシン（１−７）受容体のアゴニストとしての１−（ｐ−チエニルベンジル）イミダゾール、その製造方法、その使用およびそれらを包含する医薬製剤
JP2004533457A (ja) 2001-05-31 2004-11-04 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
JP2008535898A (ja) 2005-04-12 2008-09-04 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンｉｉアゴニスト
JP2015504870A (ja) 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
JP2018507244A (ja) 2015-03-02 2018-03-15 ビーコレ ファルマ アクティエボラーグ 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬
JP2019519586A (ja) 2016-06-29 2019-07-11 ユニヴェルシテ・ドゥ・モントリオール ビアリールメチルヘテロサイクル

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anuradha Pandey et al.，AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy，European Journal of Pharmacology，2017年，815，251-257，DOI: 10.1016/j.ejphar.2017.09.036
Xiongyu Wu et al.，Selective Angiotensin II AT2 Receptor Agonists: Arylbenzylimidazole Structure-Activity Relationships，J. Med. Chem.，2006年，49，7160-7168，DOI: 10.1021/jm0606185

Also Published As

Publication number Publication date
AU2020351301A1 (en) 2022-03-17
EP4031240A1 (en) 2022-07-27
JP2022549086A (ja) 2022-11-24
AU2020351301B2 (en) 2026-02-12
IL291172A (en) 2022-05-01
CN114786774A (zh) 2022-07-22
BR112022003130A2 (pt) 2022-05-17
CL2022000656A1 (es) 2022-11-04
GB201913603D0 (en) 2019-11-06
US20260028333A1 (en) 2026-01-29
KR20220101071A (ko) 2022-07-19
PH12022550564A1 (en) 2023-03-20
US20220388994A1 (en) 2022-12-08
US12435072B2 (en) 2025-10-07
CA3152218A1 (en) 2021-03-25
MX2022003286A (es) 2022-04-12
CO2022003091A2 (es) 2022-04-19
WO2021053344A1 (en) 2021-03-25
MX2025000262A (es) 2025-02-10
JP2026041728A (ja) 2026-03-10

Similar Documents

Publication Publication Date Title
JP7771049B2 (ja) 新化合物
CN115605265B (zh) 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物
US12441718B2 (en) Selective angiotensin II compounds
IL300582A (en) New compounds for use in the treatment of angiotensin II-related diseases
GB2605148A (en) New compounds
JP2026502510A (ja) 選択的アンジオテンシンｉｉ化合物
JP2024511451A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
JP2024511453A (ja) 選択的アンジオテンシンｉｉ受容体リガンド
EA048147B1 (ru) Новые соединения
CN117222624A (zh) 选择性血管紧张素ii受体配体
CN117916229A (zh) 新型选择性血管紧张素ii化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251105

R150 Certificate of patent or registration of utility model

Ref document number: 7771049

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150